Literature DB >> 22288460

Effects of acute pramipexole on male rats' preference for gambling-like rewards II.

Patrick S Johnson1, Gregory J Madden, Jeffrey S Stein.   

Abstract

Pramipexole (PPX) is a dopamine agonist medication that has been implicated in the development of pathological gambling and other impulse control disorders. Johnson, Madden, Brewer, Pinkston, and Fowler (2011) reported that PPX increased male rats' preference for gambling-like rewards (those arranged according to a variable-ratio schedule) over predictable rewards (those obtained from a fixed-ratio schedule). The present experiment explored the possibility that Johnson et al. underestimated the effects of PPX on gambling-like choices by constraining their rats' daily income. In the present experiment conducted in a closed economy, PPX produced a dose-related increase in choice of the gambling-like alternative. In a control condition, PPX did not disrupt choice, suggesting the increased preference for gambling-like rewards was not because of nonspecific drug effects. Our findings are qualitatively consistent with those of Johnson et al., although the dose-related effect and larger effect size in the current study suggest that the effect of PPX on gambling-like choices is more pronounced when income was not constrained. This finding is consistent with clinical reports suggesting PPX is related to the development of problem gambling in humans.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22288460      PMCID: PMC3482126          DOI: 10.1037/a0027117

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  41 in total

1.  Behavioral economics.

Authors:  S R Hursh
Journal:  J Exp Anal Behav       Date:  1984-11       Impact factor: 2.468

2.  An inexpensive infrared detector to verify the delivery of food pellets.

Authors:  Jonathan W Pinkston; Kenneth L Ratzlaff; Gregory J Madden; Stephen C Fowler
Journal:  J Exp Anal Behav       Date:  2008-09       Impact factor: 2.468

3.  Effects of acute pramipexole on preference for gambling-like schedules of reinforcement in rats.

Authors:  Patrick S Johnson; Gregory J Madden; Adam T Brewer; Jonathan W Pinkston; Stephen C Fowler
Journal:  Psychopharmacology (Berl)       Date:  2010-09-04       Impact factor: 4.530

4.  Effects of selective dopaminergic compounds on a delay-discounting task.

Authors:  Mikhail N Koffarnus; Amy H Newman; Peter Grundt; Kenner C Rice; James H Woods
Journal:  Behav Pharmacol       Date:  2011-08       Impact factor: 2.293

5.  Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study.

Authors:  Jason R Cornelius; Maja Tippmann-Peikert; Nancy L Slocumb; Courtney F Frerichs; Michael H Silber
Journal:  Sleep       Date:  2010-01       Impact factor: 5.849

6.  Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.

Authors:  Kevin J Klos; James H Bower; Keith A Josephs; Joseph Y Matsumoto; J Eric Ahlskog
Journal:  Parkinsonism Relat Disord       Date:  2005-09       Impact factor: 4.891

7.  Serotonergic and dopaminergic modulation of gambling behavior as assessed using a novel rat gambling task.

Authors:  Fiona D Zeeb; Trevor W Robbins; Catharine A Winstanley
Journal:  Neuropsychopharmacology       Date:  2009-06-17       Impact factor: 7.853

8.  Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy.

Authors:  Andrew McKeon; Keith A Josephs; Kevin J Klos; Kathleen Hecksel; James H Bower; J Michael Bostwick; J Eric Ahlskog
Journal:  Parkinsonism Relat Disord       Date:  2007-06-04       Impact factor: 4.891

9.  Brain cells in the avian 'prefrontal cortex' code for features of slot-machine-like gambling.

Authors:  Damian Scarf; Kirby Miles; Amanda Sloan; Natalie Goulter; Matt Hegan; Azade Seid-Fatemi; David Harper; Michael Colombo
Journal:  PLoS One       Date:  2011-01-25       Impact factor: 3.240

10.  Dopamine agonist increases risk taking but blunts reward-related brain activity.

Authors:  Jordi Riba; Ulrike M Krämer; Marcus Heldmann; Sylvia Richter; Thomas F Münte
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

View more
  7 in total

Review 1.  Unpredictability as a modulator of drug self-administration: Relevance for substance-use disorders.

Authors:  Sally L Huskinson
Journal:  Behav Processes       Date:  2020-06-08       Impact factor: 1.777

Review 2.  Impulse control disorders in Parkinson's disease.

Authors:  Ana Marques; Franck Durif; Pierre-Olivier Fernagut
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

3.  Pramipexole enhances disadvantageous decision-making: Lack of relation to changes in phasic dopamine release.

Authors:  Romina Pes; Sean C Godar; Andrew T Fox; Lauren M Burgeno; Hunter J Strathman; David P Jarmolowicz; Paola Devoto; Beth Levant; Paul E Phillips; Stephen C Fowler; Marco Bortolato
Journal:  Neuropharmacology       Date:  2016-11-23       Impact factor: 5.250

4.  COMT Associations with Disordered Gambling and Drinking Measures.

Authors:  Casey R Guillot; Jennifer R Fanning; Tiebing Liang; Mitchell E Berman
Journal:  J Gambl Stud       Date:  2015-06

5.  Choice between variable and fixed cocaine injections in male rhesus monkeys.

Authors:  S L Huskinson; K B Freeman; N M Petry; J K Rowlett
Journal:  Psychopharmacology (Berl)       Date:  2017-06-10       Impact factor: 4.530

6.  Mirtazapine and ketanserin alter preference for gambling-like schedules of reinforcement in rats.

Authors:  Amanda L Persons; Stephanie E Tedford; T Celeste
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-04-12       Impact factor: 5.067

7.  Choice between food and cocaine reinforcers under fixed and variable schedules in female and male rhesus monkeys.

Authors:  C Austin Zamarripa; William S Doyle; Kevin B Freeman; James K Rowlett; Sally L Huskinson
Journal:  Exp Clin Psychopharmacol       Date:  2022-01-31       Impact factor: 3.492

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.